Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study
-
Published:2024-05
Issue:
Volume:Volume 17
Page:1037-1042
-
ISSN:1178-7015
-
Container-title:Clinical, Cosmetic and Investigational Dermatology
-
language:en
-
Short-container-title:CCID
Author:
Megna Matteo,
Ruggiero AngeloORCID,
Tommasino NelloORCID,
Brescia Claudio,
Martora FabrizioORCID,
Cacciapuoti Sara,
Potestio LucaORCID
Publisher
Informa UK Limited